Vadimezan

Overview

Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes ( STING ) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING . Vadimezan has anti-influenza virus H1N1-PR8 activities.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > STING | Products > Signaling Pathways > IFNAR | Products > Signaling Pathways > Influenza Virus

Product Information

• Catalog No.: HY-10964
• CAS No.: 117570-53-3
• Molecular Formula: C17H14O4
• Molecular Weight: 282.29
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 1 mg/mL (3.54 mM); Clear solution
• Availability: In-stock

Source

Original product source